Artificial intelligence is revolutionizing health care, but developers of AI-powered medical technologies face a complex regulatory landscape shaped by the dual demands of U.S. Food and Drug Administration (FDA) oversight and U.S. patent law. While both systems aim to promote innovation and protect public interests, their interaction can create uncertainty for companies seeking to bring adaptive, data-driven tools to market, according to Matthew Carey, partner and chair of electrical and computing technologies at Marshall Gerstein IP.
Featured News
US Justice Department to Review DoorDash’s $17 Billion Instacart Deal
Nov 17, 2026 by
CPI
AstraZeneca Wins Dismissal of Soliris Antitrust Lawsuit
Nov 17, 2026 by
CPI
Sony Wins $2.64 Billion UK PlayStation Antitrust Case Over Digital Game Pricing
Nov 17, 2026 by
CPI
Spain’s Competition Regulator Plans to Turn Barcelona Headquarters Into Digital Hub
Nov 17, 2026 by
CPI
Samsung, SK Hynix and Micron Must Face US DRAM Price-Fixing Lawsuit
Nov 17, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Data Portability
Nov 12, 2026 by
CPI
Mandating Access to a Dominant Platform’s Inferred Data: A Two Scenario Diagnosis
Nov 12, 2026 by
Sean Ennis
Data Portability Between Individual Control and Data Sharing at Scale
Nov 12, 2026 by
Jasper van den Boom & Inge Graef
Information Also Wants to Be Expensive: Data Portability and the Open-Systems Creed
Nov 12, 2026 by
Justin (Gus) Hurwitz
Data Portability’s Cybersecurity Paradox: When Protecting Consumer Data Restricts Competition
Nov 12, 2026 by
Sasha Hondagneu-Messner